New Medication For Treating CRPS in 2015?  Neridronate is a new Bisphosphonate

Neridronate Approved for Fast-track status By The FDA for CRPS

Studies Began In April of 2015.

CLICK HERE FOR MORE INFORMATION ON THE NERIDRONATE TRIAL/STUDY

What’s so different about this medication?

Here are the details so far on one that was used over in Europe that showed great promise.

Neridronate is a new amino bisphosphonate for the treatment of osteopenia, but an amazing thing happened when it was tested against CRPS (#6).

As excited as we all are for the drug to be released to all CRPS patients we need to be patient, we need to let the FDA do its job of protecting us and ensuring that the drug is as safe and as effective as everyone hopes and anticipates. CRPS is a very, very complicated disease and the sympathetic and autonomic nervous systems are extremely complex. These systems affect every aspect of your body and its function so any medication that treats it, especially one that is touted as treating it so completely must be extremely potent even if it only puts it into remission.

STUDIES/TRIALS

We have a RESEARCH/TRIALS/STUDIES page you can check on for the NIH, NINDS, and ClinicalTrials.gov which will show any new studies coming out that you can sign up for if you wish to be a part of them.
You can visit that page by CLICKING HERE.

For more on this exciting news check out the article from DovePress Journal, 
Therapeutics and Clinical Risk Management;
——————-
Definitely read the article in its’ entirety and pass it along to your own Drs if necessary.

ARTICLES AND STUDIES ON NERIDRONATE 

For more on this exciting news check click on the article from DovePress Journal, 
Therapeutics and Clinical Risk Management;

1 – Clinical development of neridronate: potential for new applications 

2 – Rheumatology magazine; Volume 52, Issue 3 – Treatment of complex regional pain syndrome type I with Neridronate: a randomized, double-blind, placebo-controlled study.  Objective. Complex regional pain syndrome type I (CRPS-I) is a severely disabling pain syndrome for which no definite treatment has been established. The aim of this multi-centre, randomized, double-blind placebo-controlled trial was to test the efficacy of the amino-bisphosphonate neridronate in patients with CRP-I.

Click on the link to read the entire study and article.

3 –  Bisphosphonates For Early Complex Regional Pain Syndrome –  Neridronate, an aminobisphosphonate, has shown promise in reducing the often extreme and intransigent pain of complex regional pain syndrome. Welcomed clinically, what can this finding tell us about the enigmatic mechanisms of bisphosphonates and of complex regional pain syndrome alike?

More coming (SEE BELOW)